Skip to content

NYSE · CIK 0001855485

CLDI Calidi Biotherapeutics, Inc.

Insider trading from SEC Form 4. Last filing Aug 19, 2026. Close $0.95 on Oct 12, 2026, 0% from the 52-week low and -96% from the high.

In brief

Calidi Biotherapeutics, Inc. (CLDI) has 30 SEC Form 4 filings on file from 10 insiders, the latest filed on Aug 19, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.

6 open-market trades have been scored at CLDI. The newest: Allan Camaisa (CEO and Chairman of the Board) sold $1,237 of stock on Dec 12, 2025, filed Dec 16, 2025, scored 15 (weak). The largest of the 6 shown: Scott Leftwich (director) bought $250k on Aug 21, 2025, scored 71 (notable). 4 insiders bought within 14 days of each other around Aug 21, 2025.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company

Price and insider trades, last year

CLDIOct 12, 2026 · close 0.95

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Calidi Biotherapeutics, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
15WeakAllan Camaisa
CEO and Chairman of the Board
sell
$1,237
850 shares
-1%+9% from low-93% from high
63NotableAndrew C. Jackson
Chief Financial Officer
buy
$5,000
2,500 shares
-0% from low-96% from high
71NotableScott Leftwich
director
buy
$250k
125,000 shares
+2212%0% from low-96% from high
73NotableEric E Poma
Chief Executive Officer
buy
$50k
25,000 shares
-0% from low-96% from high
69NotableJames A Schoeneck
director
buy
$150k
75,000 shares
+6614%0% from low-96% from high
30WeakAllan Camaisa
CEO and Chairman of the Board
sell
$16k
10,000 shares
-13%-

Transactions

Every row filed, 33 in all.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Aug 17, 2026Santidrian Antonio Fernandez
Chief Scientific Officer
AGrant or award
Stock Options (right to buy)derivative
+16,000--16,000Aug 19, 2026
Aug 17, 2026Eric E Poma
Chief Executive Officer
AGrant or award
Stock Options (right to buy)derivative
+32,000--32,000Aug 19, 2026
Aug 17, 2026James A Schoeneck
director
AGrant or award
Non-Qualified Stock Options (right to buy)derivative
+5,000$0.00$05,000Aug 19, 2026
Aug 17, 2026Andrew C. Jackson
Chief Financial Officer
AGrant or award
Stock Options (right to buy)derivative
+14,000--14,000Aug 19, 2026
Aug 17, 2026Scott Leftwich
director
AGrant or award
Non-Qualified Stock Options (right to buy)derivative
+4,000$0.00$04,000Aug 19, 2026
Aug 17, 2026Alan R. Stewart
director
AGrant or award
Non-Qualified Stock Options (right to buy)derivative
+4,000$0.00$04,000Aug 19, 2026
Aug 17, 2026George Peoples
director
AGrant or award
Non-Qualified Stock Options (right to buy)derivative
+4,000$0.00$04,000Aug 19, 2026
Aug 17, 2026Corazon (Corsee) D. Sanders
director
AGrant or award
Non-Qualified Stock Options (right to buy)derivative
+6,000$0.00$06,000Aug 19, 2026
Dec 12, 2025Allan Camaisa
CEO and Chairman of the Board
SOpen-market sale
Common Stockindirect: AJC Capital, LLC
-850$1.46$1,23776,952Dec 16, 2025
Sep 3, 2025Santidrian Antonio Fernandez
Chief Scientific Officer
AGrant or award
Stock Options (right to buy)derivative
+35,000--35,000Sep 5, 2025
Sep 3, 2025Andrew C. Jackson
Chief Financial Officer
AGrant or award
Stock Options (right to buy)derivative
+30,000--30,000Sep 5, 2025
Sep 3, 2025Eric E Poma
Chief Executive Officer
AGrant or award
Stock Options (right to buy)derivative
+10,000--10,000Sep 5, 2025
Aug 21, 2025Eric E Poma
Chief Executive Officer
POpen-market purchase
Common Stock
+25,000$2.00$50k25,000Aug 25, 2025
Aug 21, 2025James A Schoeneck
director
POpen-market purchase
Common Stock
+75,000$2.00$150k76,134Aug 25, 2025
Aug 21, 2025Andrew C. Jackson
Chief Financial Officer
POpen-market purchase
Common Stock
+2,500$2.00$5,0002,500Aug 25, 2025
Aug 21, 2025Scott Leftwich
director
POpen-market purchase
Common Stock
+125,000$2.00$250k130,650Aug 25, 2025
Aug 21, 2025Andrew C. Jackson
Chief Financial Officer
POpen-market purchase
Warrant (right to buy)derivative
+2,500--2,500Aug 25, 2025
Aug 21, 2025Eric E Poma
Chief Executive Officer
POpen-market purchase
Warrant (right to buy)derivative
+25,000--25,000Aug 25, 2025
Aug 21, 2025Scott Leftwich
director
POpen-market purchase
Warrant (right to buy)derivative
+125,000--125,000Aug 25, 2025
Aug 21, 2025James A Schoeneck
director
POpen-market purchase
Warrant (right to buy)derivative
+75,000--75,000Aug 25, 2025
Jul 9, 2025Alan R. Stewart
director
AGrant or award
Non-Qualified Stock Options (right to buy)derivative
+137,078$0.00$0137,078Jul 15, 2025
Jul 9, 2025James A Schoeneck
director
AGrant or award
Non-Qualified Stock Options (right to buy)derivative
+164,493$0.00$0164,493Jul 15, 2025
Jul 9, 2025George Peoples
director
AGrant or award
Non-Qualified Stock Options (right to buy)derivative
+137,078$0.00$0137,078Jul 15, 2025
Jul 9, 2025Scott Leftwich
director
AGrant or award
Non-Qualified Stock Options (right to buy)derivative
+137,078$0.00$0137,078Jul 15, 2025
Apr 22, 2025Eric E Poma
Chief Executive Officer
AGrant or award
Stock Option (right to buy)derivative
+726,412--726,412Apr 25, 2025
Dec 31, 2024Scott Leftwich
director
AGrant or award
Common Stock
+11,684--67,774Jan 3, 2025
Dec 31, 2024Alan R. Stewart
director
AGrant or award
Common Stock
+12,771--28,976Jan 3, 2025
Dec 17, 2024Allan Camaisa
CEO and Chairman of the Board
SOpen-market sale
Common Stock
-10,000$1.62$16k66,712Dec 18, 2024
Sep 20, 2024Scott Leftwich
director
AGrant or award
Non-Qualified Stock Options (right to buy)derivative
+20,217--20,217Oct 15, 2024
Sep 20, 2024George Peoples
director
AGrant or award
Non-Qualified Stock Options (right to buy)derivative
+20,217--20,217Oct 15, 2024
Sep 20, 2024James A Schoeneck
director
AGrant or award
Non-Qualified Stock Options (right to buy)derivative
+20,217--20,217Oct 15, 2024
Sep 20, 2024Alan R. Stewart
director
AGrant or award
Non-Qualified Stock Options (right to buy)derivative
+20,217--20,217Oct 15, 2024
Dec 21, 2023Thomas A. Vecchiolla
director
AGrant or award
Common Stock
+7,709$1.80$14k365,105Dec 26, 2023

Insiders

Everyone who has filed a Form 4 here.

Questions about CLDI

Answered from the filings on this page, as of the latest one.

Are insiders buying CLDI?

No. In the last 90 days no insider at Calidi Biotherapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.

Who was the last insider to trade CLDI on the open market?

Allan Camaisa (CEO and Chairman of the Board) sold $1,237 of CLDI on Dec 12, 2025 and filed the Form 4 on Dec 16, 2025. InsiderTell scored 15 (weak).

How many insiders file Form 4 at Calidi Biotherapeutics, Inc.?

10 people have filed a Form 4 at Calidi Biotherapeutics, Inc., among them Allan Camaisa (CEO and Chairman of the Board), Santidrian Antonio Fernandez (Chief Scientific Officer), Andrew C. Jackson (Chief Financial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

CLDI insider trading: Calidi Biotherapeutics, Inc. | InsiderTell